OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacoeconomics is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)	534
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?	199
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”	86
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling	82
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis	81
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment	80
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment	59
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	52
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment	47
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting	43
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children	39
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy	38
Advancing Methods to Measure and Reward Healthcare Innovation	36
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States	36
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation	33
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies	31
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA	31
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review	28
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy	27
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review	27
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)	26
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned	26
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS	25
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling	24
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition	24

Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based	24
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review	24
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions	24
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment	24
An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada	23
Mixture and Non-mixture Cure Models for Health Technology Assessment: What You Need to Know	23
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review	23
The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review	23
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective	22
Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap	22
The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations	22
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes	21
Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey	20
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries	19
Market Transparency in Medicine Pricing: Pathways to Fair Pricing	19
Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review	18
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)	18
Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators	17
Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries	17
Quality Appraisal in Systematic Literature Reviews of Studies Eliciting Health State Utility Values: Conceptual Considerations	16
Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program	16
Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs	16
Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework	16
Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia	16
Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD)	16
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds	15
Prognostic Testing for Prostate Cancer—A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice	15
Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models	15
Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia	14
Acknowledgement to Referees	14
A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models	14
Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies	14
A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates	14
Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated	14
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry	14
Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents	13
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis	12
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer	12
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant Protection	12
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Mye	12
Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Base	12
Modelling the Cost-Effectiveness of Diagnostic Tests	12
Comment on Keeney et al.’s “Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening”	12
Examining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria	12
Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis	12
Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)	11
Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics	11
Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review	11
Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments	11
Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations	11

Systematic Review of Conceptual, Age, Measurement and Valuation Considerations for Generic Multidimensional Childhood Patient-Reported Outcome Measures	11
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China	11
Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”	11
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom	11
Uncertainty in Matching-Adjusted Indirect Comparisons Using Real-World Evidence: Evidence Assessment Group Perspective	11
What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK	11
Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability	11
Systematic Review of the Relative Social Value of Child and Adult Health	11
Childhood Transitions Between Weight Status Categories: Evidence from the UK Millennium Cohort Study	11
A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework	11
Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA	11
A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper	10
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer	10
Economic Implications of Endometriosis: A Review	10
Examining the Effect of Depicting a Patient Affected by a Negative Reimbursement Decision in Healthcare on Public Disagreement with the Decision	10
Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review	10
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments	10
The Costs of Dementia in Europe: An Updated Review and Meta-analysis	10
Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods	10
Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?	10
How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review	10
Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study	10
Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review	9
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan	9
Universal Health Coverage of Opioid Agonist Treatment in Norway: An Equity-Adjusted Economic Evaluation	9
A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process	9
Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L	9
Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort	9
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias	9
Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses	9
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meni	9
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom	9
Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges	9
A Value Set for the EQ-5D-Y-3L in the Netherlands	9
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study	9
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel	9
Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer	9
Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments	8
Incorporating Complexity and System Dynamics into Economic Modelling for Mental Health Policy and Planning	8
A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome	8
Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening	8
HTA Barriers for Conditional Approval Drugs	8
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study	8
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK	8
Valuing SF-6Dv2 in Australia Using an International Protocol	8
Using AI in the Economic Evaluation of AI-Based Health Technologies	8
MPES-R: Multi-Parameter Evidence Synthesis in R for Survival Extrapolation—A Tutorial	8
Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time	8
Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment	8
PharmacoEconomics Supplement	8
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA	8
Measuring Effectiveness Based on Patient Experience (Instead of QALYs) in US Value Assessments	8